000041979 000__ 02089cam\a22002535i\4500 000041979 001__ 41979 000041979 003__ SzGeWIPO 000041979 005__ 20210318105245.0 000041979 008__ 200622s2017\\\\sz\\\\\\r\\\\\000\0\eng\d 000041979 022__ $$a0736-7694 000041979 040__ $$aSzGeWIPO$$beng$$erda 000041979 041__ $$aeng 000041979 1001_ $$aCosta, Kenneth J. 000041979 24503 $$aPatent System Manipulation :$$bHedge Funds Abusing IPR, Poor Patent Quality & Pharmaceutical Monopolies 000041979 264_1 $$a[New York City, New York] :$$bYeshiva University Benjamin N. Cardozo School of Law,$$c2017. 000041979 300__ $$a32 pages 000041979 336__ $$atext$$btxt$$2rdacontent 000041979 337__ $$aunmediated$$bn$$2rdamedia 000041979 338__ $$avolume$$bnc$$2rdacarrier 000041979 520__ $$aThis Note explores the abuses to IPR and the stock market by hedge funds, and abuses by pharmaceutical companies to the patent system as a whole, and poses a solution that will prevent these abuses. In Part I, this Note will discuss patent basics, the PTAB’s role, and the IPR process. It will also examine, in detail, the patent trolling technique hedge funds are using. Additionally, it will address what actions the PTAB has taken, and is likely to take, if any, to prevent the hedge funds’ conduct. Lastly, Part I will explore the monopolistic hold the pharmaceutical industry has on drug pricing. Part II of this Note will examine the legislative responses to hedge funds’ abuse of IPR by analyzing proposed patent reform bills in Congress, and whether those bills will affect the problem at hand. This Part will also address the pharmaceutical industry’s push for an exception to IPR. In Part III of this Note, a policy solution will be proposed that advocates for higher standards for pharmaceutical companies to obtain drug patents, and for regulatory changes that allow for quicker entry to the market by generics. Moreover, Part III will discuss how these policies can be implemented and why they will work. 000041979 525__ $$aPublished in : Cardozo Arts & Entertainment Law, vol. 35, no. 1 (2017) 000041979 650_0 $$aPatents 000041979 650_0 $$aPharmaceuticals 000041979 650_0 $$aHedge fund 000041979 85641 $$uhttp://www.cardozoaelj.com/wp-content/uploads/2017/02/35.1-Costa.pdf$$yView this resource 000041979 904__ $$aArticle 000041979 980__ $$aBIB